Evidence map›Paper›PMID 37446914›Full record

ArticleMolecules (Basel, Switzerland)2023

Combination of an Oxindole Derivative with (-)-β-Elemene Alters Cell Death Pathways in FLT3/ITD

Jowaher Alanazi, Onur Bender, Rumeysa Dogan, Jonaid Ahmad Malik, Arzu Atalay, Taha F S Ali, Eman A M Beshr, Ahmed M Shawky, Omar M Aly, Yasir Nasser H Alqahtani and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 4 countries.

Jowaher AlanaziDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Hail, Hail 55476, Saudi Arabia.
Onur BenderBiotechnology Institute, Ankara University, Ankara 06135, Turkey.ORCID 0000-0003-0691-3508
Rumeysa DoganBiotechnology Institute, Ankara University, Ankara 06135, Turkey.
Jonaid Ahmad MalikDepartment of Biomedical Engineering, Indian Institute of Technology Ropar, Rupnagar 140001, India.ORCID 0000-0001-6684-6744
Arzu AtalayBiotechnology Institute, Ankara University, Ankara 06135, Turkey.ORCID 0000-0003-1309-5291
Taha F S AliDepartment of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.ORCID 0000-0002-8881-0408
Eman A M BeshrDepartment of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
Ahmed M ShawkyScience and Technology Unit (STU), Umm Al-Qura University, Makkah 21955, Saudi Arabia.ORCID 0000-0002-3035-661X
Omar M AlyDepartment of Medicinal Chemistry, Faculty of Pharmacy, Port Said University, Port Said 42511, Egypt.
Yasir Nasser H AlqahtaniMOI Clinics, Security Forces Hospital, Riyadh 11481, Saudi Arabia.
Sirajudheen AnwarDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Hail, Hail 55476, Saudi Arabia.ORCID 0000-0002-0926-2790
Ankara University · TRMinia University · EGUniversity of Ha'il · SAIndian Institute of Technology Ropar · INPort Said University · EGSecurity Forces Hospital · SAUmm al-Qura University · SA

Funding

University of Hail BA-23 007.
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is one of the cancers that grow most aggressively. The challenges in AML management are huge, despite many treatment options. Mutations in FLT3 tyrosine kinase receptors make the currently available therapies less responsive. Therefore, there is a need to find new lead molecules that can specifically target mutated FLT3 to block growth factor signaling and inhibit AML cell proliferation. Our previous studies on FLT3-mutated AML cells demonstrated that β-elemene and compound

Indexed as

Leukemia, Myeloid, AcuteApoptosisCell Line, Tumorfms-Like Tyrosine Kinase 3HumansMutationOxindolesProtein Kinase InhibitorsSesquiterpenesbeta-elemeneFLT3 protein, humanfms-Like Tyrosine Kinase 3OxindolesProtein Kinase InhibitorsSesquiterpenesacute myeloid leukemiaFLT3ITDMV4-11oxindolesynergyfinderβ-elemene

Identifiers

PMID37446914
PMCPMC10343312
OpenAlexW4383550941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.